Australia Anemia in Pregnancy Market, By Cause (Folic Acid Deficiency, Iron Deficiency, Vitamin B12 Deficiency, and Others), Treatment (Iron Products, Folic Acid Supplementation, and Others), Route of Administration (Oral, Intravenous, and Intramuscular), Prescribing Weeks (< 13 Weeks, 13-27 Weeks and ≥28 Weeks), End User (Hospitals, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others) – Industry Trends and Forecast to 2030.
Australia Anemia in Pregnancy Market Analysis and Size
Anemia is one of the most widespread blood disorders in recent times. The growing R&D in developing new treatment options and advancements in diagnostic procedures is anticipated to increase the growth of anemia in the pregnancy market. Deficiency of iron in women is the most common cause of anemia during pregnancy. The incidence of anemia in pregnancy was higher than previously estimated in Australia, being more common in the tertiary public hospital setting and with advancing gestation.
Data Bridge Market Research analyses a growth rate in the anemia in the pregnancy market in the forecast period 2023-2030. The expected CAGR of anemia in the pregnancy market tends to be around 8.8% in the mentioned forecast period. The market was valued at USD 160.71 million in 2022 and would grow to USD 315.55 million by 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Australia Anemia in Pregnancy Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2030
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Cause (Folic Acid Deficiency, Iron Deficiency, Vitamin B12 Deficiency, and Others), Treatment (Iron Products, Folic Acid Supplementation, and Others), Route of Administration (Oral, Intravenous, and Intramuscular), Prescribing Weeks (< 13 Weeks, 13-27 Weeks and ≥28 Weeks), End User (Hospitals, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others)
|
|
Market Players Covered
|
Viatris Inc.(U.S.), Aspen Pharmacare Australia Pty Ltd (Australia), PharmaCare Laboratories Australia (Australia), AFT Pharmaceuticals (New Zealand), Bayer AG (Germany), A Nelson & Co Ltd (U.K.), BLACKMORES (Australia) and Care Pharma (India)
|
|
Market Opportunities
|
|
Market Definition
Anemia is a condition when the body does not have produce enough red blood cells to carry oxygen to tissues. Anemia during pregnancy is common as the body requires enough blood to support the baby's growth. The normal nutrients taken by a woman are not enough when conceiving, as there is a high requirement for iron and folate during the second and third trimesters of pregnancy. Mild anemia is usually witnessed in every pregnant woman, but the severity rises because of low iron or vitamin levels in the body and other reasons.
Australia Anemia in Pregnancy Market Dynamics
Drivers
- Increasing Incidence of Anemia
Anaemia is a prevalent condition witnessed in Australia and around the world, affecting more than 1.5 billion people globally. It is particularly widespread in certain populations: in Australia, about 12 percent of women, 8 percent of pre-school-aged children, and 20 percent of people over 85 years are anemic. The burden of anemia among the Australian population is higher than in the general population, despite high anemia prevalence. According to the National Heart, Lung, and Blood Institute, an expected 3 million individuals suffer from anemia in Australia. The growing incidence of target diseases, such as rheumatoid arthritis, kidney conditions, autoimmune diseases, liver disorders, thyroid diseases, cancer, and inflammatory bowel diseases, is a primary factor helping the market's growth. Thus, this boosts the growth of the market.
Opportunities
- Growing Prevalence of Chronic Kidney Disease
According to the National Kidney Foundation, Inc. statistics, the two main causes of chronic kidney disease (CKD) are diabetes and hypertension. More than 1 in 7, around 15% of Australian adults, are projected to have CKD. In 2017-18, around 1.0% of Australians had kidney disease. The incidence of kidney disease has remained relatively stable since 2011-12. It is anticipated that the prevalence of chronic kidney cases will rise across highly economic countries, such as the U.S., which infers an increase in the aged population over the upcoming years.
- Increasing Agreements and Collaborations
Several contracts and agreements are initiated by the market players globally who are also increasing the anemia in the pregnancy market. For instance, Viatris Inc. announced in 2021 that the company participated in the 42nd Annual Global Healthcare Conference of Goldman Sachs, which was organized on June 10, 2021. The company's chief executive officer and the president will answer any queries associated with the company by globally attended customers. This is anticipated to increase the company's recognition. This creates more opportunities in the market.
Restraints/Challenges
- Adverse Effects of Iron Supplements
Few serious effects are related to the intake of iron drugs. Common effects include digestive problems such as nausea, stomach aches, loss of appetite, constipation, and vomiting. The high dose of these drugs may also cause tiredness or weakness, shallow or rapid breathing, bluish skin, fatigue, convulsions, pale skin, or fingernails. Thus, this impedes market growth.
This anemia in pregnancy market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the anemia in pregnancy market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Australia Anemia in Pregnancy Market Scope
The anemia in pregnancy market is segmented on the basis of cause, treatment, route of administration, prescribing weeks, end user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Cause
- Folic Acid Deficiency
- Iron Deficiency
- Vitamin B12 Deficiency
- Others
Treatment
- Iron Products
- Folic Acid Supplementation
- Others
Route of Administration
- Oral
- Intravenous
- Intramuscular
Weeks
- < 13 Weeks
- 13-27 Weeks
- ≥28 Weeks
End-Users
- Hospitals
- Specialty Clinics
- Home Healthcare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Competitive Landscape and Australia Anemia in Pregnancy Market Share Analysis
The anemia in pregnancy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Australia presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to anemia in pregnancy market.
Key players operating in the anemia in pregnancy market include:
- Viatris Inc. (U.S.)
- Aspen Pharmacare Australia Pty Ltd (Australia)
- PharmaCare Laboratories Australia (Australia)
- AFT Pharmaceuticals (New Zealand)
- Bayer AG (Germany)
- A Nelson & Co Ltd (U.K.)
- BLACKMORES (Australia)
- Care Pharma (India)
SKU-